Association between serum 25-Hydroxyvitamin D level and subclinical cardiovascular disease in primary hyperparathyroidism

Journal of Clinical Endocrinology and Metabolism

Volumn 99, Issue 2, 2014, Pages 671-680

  Walker, Marcella D ^a   Cong, Elaine ^a   Kepley, Anna ^a   Di Tullio, Marco R ^a   Rundek, Tatjana ^c   Homma, Shunichi ^a   Lee, James A ^b   Liu, Rui ^a   Young, Polly ^a   Zhang, Chiyuan ^a   McMahon, Donald J ^a   Silverberg, Shonni J ^a  

^a Departments of Preventive Medicine   (United States)

^b Och Spine at New York Presbyterian Hospitals   (United States)

^c UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

25 HYDROXYVITAMIN D; CALCIUM; PHOSPHATE;

ADULT; ARTERIAL STIFFNESS; ARTERIAL WALL THICKNESS; ARTICLE; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; FEMALE; HEART LEFT VENTRICLE MASS; HUMAN; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; NEPHROLITHIASIS; PHOSPHATE BLOOD LEVEL; PRIMARY HYPERPARATHYROIDISM; PRIORITY JOURNAL; RELAXATION TIME; TISSUE DOPPLER IMAGING; TRANSTHORACIC ECHOCARDIOGRAPHY; UNIVERSITY HOSPITAL; VITAMIN BLOOD LEVEL;

AGED; CARDIOVASCULAR DISEASES; CAROTID INTIMA-MEDIA THICKNESS; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; HYPERPARATHYROIDISM, PRIMARY; MALE; MIDDLE AGED; RISK FACTORS; VITAMIN D; VITAMIN D DEFICIENCY;

EID: 84896707336     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2013-3523     Document Type: Article

References (57)

1. Scragg R, Jackson R, Holdaway IM, Lim T, Beaglehole R. Myocardial infarction is inversely associated with plasma 25-hydroxyvitamin D3 levels: a community-based study. Int J Epidemiol. 1990; 19:559-563.
2. Scragg R. Seasonality of cardiovascular disease mortality and the possible protective effect of ultra-violet radiation. Int J Epidemiol. 1981;10:337-341.
3. Artaza JN, Mehrotra R, Norris KC. Vitamin D and the cardiovascular system. Clin J Am Soc Nephrol. 2009;4:1515-1522.
4. Dobnig H, Pilz S, Scharnagl H, et al. Independent association of low serum 25-hydroxyvitamin d and 1,25-dihydroxyvitamin d levels with all-cause and cardiovascular mortality. Arch InternMed. 2008; 168:1340-1349.
5. Melamed ML, Michos ED, Post W, Astor B. 25-Hydroxyvitamin D levels and the risk of mortality in the general population. Arch Intern Med. 2008;168:1629-1637.
6. Pilz S, Marz W, Wellnitz B, et al. Association of vitaminDdeficiency with heart failure and sudden cardiac death in a large cross-sectional study of patients referred for coronary angiography. J Clin Endocrinol Metab. 2008;93:3927-3935.
7. Wang TJ, Pencina MJ, Booth SL, et al. VitaminDdeficiency and risk of cardiovascular disease. Circulation. 2008;117:503-511.
8. Giovannucci E, Liu Y, Hollis BW, Rimm EB. 25-HydroxyvitaminD and risk of myocardial infarction in men: a prospective study. Arch Intern Med. 2008;168:1174-1180.
9. Welsh P, Doolin O, McConnachie A, et al. Circulating 25OHD, dietary vitamin D, PTH, and calcium associations with incident cardiovascular disease and mortality: the MIDSPAN Family Study. J Clin Endocrinol Metab. 2012;97:4578-4587.
10. Karakas M, Thorand B, Zierer A, et al. Low levels of serum 25- hydroxyvitamin D are associated with increased risk of myocardial infarction, especially in women: results from the MONICA/KORA Augsburg Case-Cohort Study. J Clin Endocrinol Metab. 2013;98: 272-280.
11. Wang L, Song Y, Manson JE, et al. Circulating 25-hydroxy-vitamin D and risk of cardiovascular disease: a meta-analysis of prospective studies. Circ Cardiovasc Qual Outcomes. 2012;5:819-829.
12. Moosgaard B, Vestergaard P, Heickendorff L, Melsen F, Christiansen P, Mosekilde L. Vitamin D status, seasonal variations, parathyroid adenoma weight and bone mineral density in primary hyperparathyroidism. Clin Endocrinol (Oxf). 2005;63:506-513.
13. Clements MR, Davies M, Hayes ME, et al. The role of 1,25- dihydroxyvitaminDin the mechanism of acquired vitaminDdeficiency. Clin Endocrinol (Oxf). 1992;37:17-27.
14. Shane E, Mancini D, Aaronson K, et al. Bone mass, vitamin D deficiency, and hyperparathyroidism in congestive heart failure. Am J Med. 1997;103:197-207.
15. Boudou P, Ibrahim F, Cormier C, Sarfati E, Souberbielle JC. A very high incidence of low 25 hydroxy-vitaminDserum concentration in a French population of patients with primary hyperparathyroidism. J Endocrinol Invest. 2006;29:511-515.
16. Yamashita H, Noguchi S, Uchino S, et al. Vitamin D status in Japanese patients with hyperparathyroidism: seasonal changes and effect on clinical presentation. World J Surg. 2002;26:937-941.
17. Clements MR, Davies M, Fraser DR, Lumb GA, Mawer EB, Adams PH. Metabolic inactivation of vitamin D is enhanced in primary hyperparathyroidism. Clin Sci (Lond). 1987;73:659-664.
18. Dalberg K, Brodin LA, Juhlin-Dannfelt A, Farnebo LO. Cardiac function in primary hyperparathyroidism before and after operation. An echocardiographic study. Eur J Surg. 1996;162:171-176.
19. Piovesan A, Molineri N, Casasso F, et al. Left ventricular hypertrophy in primary hyperparathyroidism. Effects of successful parathyroidectomy. Clin Endocrinol (Oxf). 1999;50:321-328.
20. Stefenelli T, Abela C, Frank H, et al. Cardiac abnormalities in patients with primary hyperparathyroidism: implications for followup. J Clin Endocrinol Metab. 1997;82:106-112.
21. Walker MD, Fleischer J, Rundek T, et al. Carotid vascular abnormalities in primary hyperparathyroidism. J Clin Endocrinol Metab. 2009;94:3849-3856.
22. Walker MD, Silverberg SJ. Cardiovascular aspects of primary hyperparathyroidism. J Endocrinol Invest. 2008;31:925-931.
23. Nappi S, Saha H, Virtanen V, et al. Left ventricular structure and function in primary hyperparathyroidism before and after parathyroidectomy. Cardiology. 2000;93:229-233.
24. Rubin MR, Maurer MS, McMahon DJ, Bilezikian JP, Silverberg SJ. Arterial stiffness in mild primary hyperparathyroidism. J Clin Endocrinol Metab. 2005;90:3326-3330.
25. Iwata S, Walker MD, Di Tullio MR, et al. Aortic valve calcification in mild primary hyperparathyroidism. J Clin Endocrinol Metab. 2012;97:132-137.
26. WalkerMD,Fleischer JB, Di TullioMR,et al. Cardiac structure and diastolic function in mild primary hyperparathyroidism. J Clin Endocrinol Metab. 2010;95:2172-2179.
27. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999;130:461-470.
28. Rundek T, Elkind MS, Pittman J, et al. Carotid intima-media thickness is associated with allelic variants of stromelysin-1, interleukin- 6, and hepatic lipase genes: the Northern Manhattan Prospective Cohort Study. Stroke. 2002;33:1420-1423.
29. Juo SH, Lin HF, Rundek T, et al. Genetic and environmental contributions to carotid intima-media thickness and obesity phenotypes in the Northern Manhattan Family Study. Stroke. 2004;35:2243-2247.
30. O'Leary DH, Polak JF, Kronmal RA, Manolio TA, Burke GL, Wolfson SK Jr. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group. N Engl J Med 1999; 340:14-22.
31. Lang RM BM, Devereux RB, Flachskampf FA, et al. Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr. 2005;18:1440-1463.
32. Devereux RB, Alonso DR, Lutas EM, et al. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol. 1986;57:450-458.
33. Ambrogini E, Cetani F, Cianferotti L, et al. Surgery or surveillance for mild asymptomatic primary hyperparathyroidism: a prospective, randomized clinical trial. J Clin Endocrinol Metab. 2007;92: 3114-3121.
34. Sun Q, Pan A, Hu FB, Manson JE, Rexrode KM. 25-Hydroxyvitamin D levels and the risk of stroke: a prospective study and metaanalysis. Stroke. 2012;43:1470-1477.
35. Ginde AA, Scragg R, Schwartz RS, Camargo CA Jr. Prospective study of serum 25-hydroxyvitamin D level, cardiovascular disease mortality, and all-cause mortality in older US adults. J Am Geriatr Soc. 2009;57:1595-1603.
36. Robinson-Cohen C, Hoofnagle AN, Ix JH, et al. Racial differences in the association of serum 25-hydroxyvitamin D concentration with coronary heart disease events. JAMA. 2013;310:179-188.
37. Amer M, Qayyum R. Relationship between 25-hydroxyvitamin D and all-cause and cardiovascular disease mortality.AmJMed. 2013; 126:509-514.
38. Schottker B, Haug U, Schomburg L, et al. Strong associations of 25-hydroxyvitamin D concentrations with all-cause, cardiovascular, cancer, and respiratory disease mortality in a large cohort study. Am J Clin Nutr. 2013;97:782-793.
39. Xiang W, Kong J, Chen S, et al. Cardiac hypertrophy in vitamin D receptor knockout mice: role of the systemic and cardiac renin-angiotensin systems. Am J Physiol Endocrinol Metab. 2005;288: E125-E132.
40. Li YC, Qiao G, Uskokovic M, Xiang W, Zheng W, Kong J. Vitamin D: a negative endocrine regulator of the renin-angiotensin system and blood pressure. J Steroid Biochem Mol Biol. 2004;89-90:387-392.
41. LiYC,KongJ,WeiM,ChenZF, Liu SQ,CaoLP. 1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system. J Clin Invest. 2002;110:229-238.
42. Sun J, Kong J, Duan Y, et al. Increased NF-κB activity in fibroblasts lacking the vitamin D receptor. Am J Physiol Endocrinol Metab. 2006;291:E315-E322.
43. Andress DL. VitaminDin chronic kidney disease: a systemic role for selective vitaminDreceptor activation. Kidney Int. 2006;69:33-43.
44. Carrelli AL, Walker MD, Lowe H, et al. Vitamin D deficiency is associated with subclinical carotid atherosclerosis: the Northern Manhattan study. Stroke. 2011;42:2240-2245.
45. Wood AD, Secombes KR, Thies F, et al. Vitamin D3 supplementation has no effect on conventional cardiovascular risk factors: a parallel-group, double-blind, placebo-controlled RCT. J Clin Endocrinol Metab. 2012;97:3557-3568.
46. Yiu YF, Yiu KH, Siu CW, et al. Randomized controlled trial of vitamin D supplement on endothelial function in patients with type 2 diabetes. Atherosclerosis. 2013;227:140-146.
47. Gepner AD, Ramamurthy R, Krueger DC, Korcarz CE, Binkley N, Stein JH. A prospective randomized controlled trial of the effects of vitamin D supplementation on cardiovascular disease risk. PLoS One. 2012;7:e36617.
48. Institute of Medicine. Dietary Reference Intakes for Calcium and Vitamin D. Washington, DC: Institute of Medicine; 2010. http:// www.iom.edu/reports/ 2010/Dietary-Reference-Intake-for-calciumand- vitamin-D.aspx.
49. Holick MF, Binkley NC, Bischoff-Ferrari HA, et al. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011; 96:1911-1930.
50. Durazo-Arvizu RA, Dawson-Hughes B, Sempos CT, et al. Threephase model harmonizes estimates of the maximal suppression of parathyroid hormone by 25-hydroxyvitamin D in persons 65 years of age and older. J Nutr. 2010;140:595-599.
51. Eastell R, Arnold A, Brandi ML, et al. Diagnosis of asymptomatic primary hyperparathyroidism: proceedings of the third international workshop. J Clin Endocrinol Metab. 2009;94:340-350.
52. Silverberg SJ, Shane E, Dempster DW, Bilezikian JP. The effects of vitamin D insufficiency in patients with primary hyperparathyroidism. Am J Med. 1999;107:561-567.
53. Bilezikian JP, Meng X, Shi Y, Silverberg SJ. Primary hyperparathyroidism in women: a tale of two cities-New York and Beijing. Int J Fertil Womens Med. 2000;45:158-165.
54. Bandeira F, Griz L, Caldas G, Bandeira C, Freese E. From mild to severe primary hyperparathyroidism: the Brazilian experience. Arq Bras Endocrinol Metab. 2006;50:657-663.
55. Rao DS, Agarwal G, Talpos GB, et al. Role of vitaminDand calcium nutrition in disease expression and parathyroid tumor growth in primary hyperparathyroidism: a global perspective. J Bone Miner Res 2002;2(suppl 17):N75-N80.
56. Roberts WC, Waller BF. Effect of chronic hypercalcemia on the heart. An analysis of 18 necropsy patients. Am J Med. 1981;71: 371-384.
57. Bischoff-Ferrari H. Vitamin D: what is an adequate vitamin D level and how much supplementation is necessary? Best Pract Res Clin Rheumatol. 2009;23:789-795.